CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7,500,000 Shares of its Common Stock

06 Mar 2023 05:00:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2022 Audited Financial Results and Provides Corporate Update

28 Feb 2023 13:05:01 By Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference Call

14 Feb 2023 13:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation

13 Feb 2023 05:00:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Provides Miricorilant Clinical Development Update

08 Dec 2022 05:00:02 By Nasdaq GlobeNewswire

Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals

08 Dec 2022 05:00:01 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

03 Nov 2022 13:05:02 By Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

27 Oct 2022 13:05:01 By Nasdaq GlobeNewswire

Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)

11 Oct 2022 13:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

03 Aug 2022 13:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer

29 Jun 2022 13:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics to Start Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer

06 Jun 2022 05:00:02 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces First Quarter Financial Results And Provides Corporate Update

05 May 2022 13:05:01 By Nasdaq GlobeNewswire

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

28 Apr 2022 13:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Appointment of Three Senior Leaders

07 Apr 2022 13:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Completes Enrollment in Phase 2 GRATITUDE Study of Miricorilant in Patients with Antipsychotic-Induced Weight Gain

04 Apr 2022 13:05:00 By Nasdaq GlobeNewswire

Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Recurrent, Platinum-resistant Ovarian Cancer

30 Mar 2022 13:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics to Host Ovarian Cancer Program Update on Thursday, March 31, 2022

01 Mar 2022 13:05:01 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2021 Audited Financial Results and Provides Corporate Update

15 Feb 2022 13:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Fourth Quarter and Full-year 2021 Financial Results, Provide Corporate Update and Host Conference Call

08 Feb 2022 13:05:00 By Nasdaq GlobeNewswire